Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
about
MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.The podocyte as a direct target for treatment of glomerular disease?ACTH action on podocytes: mystery solved?Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.Adrenomedullin ameliorates podocyte injury induced by puromycin aminonucleoside in vitro and in vivo through modulation of Rho GTPases.Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization
P2860
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@en
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@nl
type
label
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@en
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@nl
prefLabel
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@en
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.
@nl
P2093
P2860
P1476
Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation
@en
P2093
Anna Granqvist
Annika Lindskog Jonsson
Börje Haraldsson
Emelie Lassén
Jenny Nyström
Lovisa Bergwall
P2860
P304
P356
10.1152/AJPRENAL.00231.2015
P577
2016-02-17T00:00:00Z